Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) once-weekly in participants with overweight or obesity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509273-24-00

Acronym

NN9838-7749

Enrollment

100

Registered

2024-06-26

Start date

2024-09-05

Completion date

Unknown

Last updated

2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Relative change in body weight, Achievement of ≥5% weight reduction

Detailed description

Achievement of ≥10 % weight reduction, Achievement of ≥15% weight reduction, Achievement of ≥20% weight reduction, Change in waist circumference, Change in systolic blood pressure, Ratio to baselin in lipids: Total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, Triglycerids, Free fatty acids

Interventions

DRUGcagrilintide semaglutide

DRUGPlacebo + Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Relative change in body weight, Achievement of ≥5% weight reduction	—

Secondary

Measure	Time frame
Achievement of ≥10 % weight reduction, Achievement of ≥15% weight reduction, Achievement of ≥20% weight reduction, Change in waist circumference, Change in systolic blood pressure, Ratio to baselin in lipids: Total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, Triglycerids, Free fatty acids	—

Countries

France, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026